Cero Therapeutics Reports $15.4 Million Net Loss and Seeks Additional Funding

Cero Therapeutics Holdings, Inc. reported a net loss of $15.4 million for the nine months ending September 30, 2025, a significant increase from the $9 million loss during the same period in 2024. The company's total operating expenses for the nine months were approximately $14 million, slightly down from $14.1 million in the previous year. Research and development expenses rose by 30.7% to $8 million, driven by increased clinical trial costs associated with the company's lead compound, CER-1236, which is currently in Phase 1 clinical trials for acute myeloid leukemia (AML). General and administrative expenses decreased by 24.6% to $6 million, primarily due to reduced professional fees.

In terms of financial position, Cero Therapeutics reported cash and cash equivalents of approximately $2 million as of September 30, 2025, down from $3.3 million at the end of 2024. The company has an accumulated deficit of $86.3 million, reflecting its ongoing investment in research and development without generating revenue. The company has not yet commercialized any products and does not expect to do so in the near term. The financial statements indicate a need for additional capital to fund ongoing operations and R&D activities.

Cero Therapeutics has made strategic moves to bolster its financial position, including entering into a Fifth Securities Purchase Agreement to issue up to 9,750 shares of Series E Preferred Stock for up to $7 million. The company also completed several rounds of financing, including the sale of Series D Preferred Stock, which raised approximately $2.6 million. However, the company faces challenges, including a recent delisting from the Nasdaq stock exchange, which has led to its shares trading on the OTC Pink Sheets. This transition may impact liquidity and the ability to raise future capital.

Operationally, the company has made progress with its clinical trials, having dosed multiple patients in the ongoing trials for CER-1236. The FDA has granted both Orphan Drug Designation and Fast Track Designation for this compound, which may facilitate its development and regulatory approval process. Despite these advancements, the company acknowledges the inherent risks and uncertainties in drug development, including the potential for delays or failures in clinical trials, which could significantly affect its financial outlook and operational plans.

Looking ahead, Cero Therapeutics emphasizes the need for substantial additional funding to support its R&D efforts and operational costs. The company is actively pursuing various financing options but acknowledges that the availability of capital may be limited. The management's ability to execute its business strategy will depend on successfully navigating these financial challenges while advancing its clinical programs.